```html

Uterine Arteriovenous Malformation (UAVM)

Overview

Uterine arteriovenous malformation (UAVM) is a rare vascular anomaly in which abnormal connections form directly between uterine arteries and veins, bypassing the normal capillary network. These high‑flow lesions can cause life‑threatening uterine bleeding.

• Who it affects: Primarily women of reproductive age (late teens to early 40s), but cases have been reported in post‑menopausal women.
• Prevalence: The exact prevalence is unknown due to under‑diagnosis, but estimates range from 0.1 to 1 per 10,000 women undergoing evaluation for abnormal uterine bleeding (Mayo Clinic, 2023).
• Nature: UAVMs can be congenital (present at birth) or acquired after uterine trauma such as surgery, dilation & curettage (D&C), or childbirth.

Symptoms

The presentation varies from subtle spotting to massive hemorrhage. Common symptoms include:

• Vaginal bleeding: Ranges from intermenstrual spotting to profuse, sudden bleeding that may be heavier than a typical menstrual period.
• Pelvic pain or cramping: Often coincides with bleeding episodes.
• Dyspareunia: Pain during intercourse due to uterine congestion.
• Anemia-related fatigue: Resulting from chronic blood loss.
• Fertility issues: Some women experience difficulty conceiving, although many retain fertility after treatment.
• Hemodynamic instability: In severe cases, rapid heart rate, dizziness, or fainting may occur due to acute blood loss.

Causes and Risk Factors

Congenital UAVM

These arise from developmental errors in the vascular system during embryogenesis. They are extremely rare and often identified only when symptomatic.

Acquired UAVM

Most UAVMs are acquired and linked to uterine trauma. The mechanisms involve:

• Surgical procedures: Cesarean section, myomectomy, hysterectomy, or endometrial ablation.
• Dilation & curettage (D&C) or suction curettage: Particularly after miscarriage or termination.
• Uterine instrumentation: Hysteroscopic polypectomy, uterine artery embolization (paradoxically, embolization can sometimes create a secondary AVM).
• Placental abnormalities: Placenta previa or accreta can predispose to abnormal vascular remodeling.

Risk Factors

• History of uterine surgery or invasive procedures.
• Multiple prior pregnancies, especially with cesarean delivery.
• Previous episodes of severe postpartum hemorrhage.
• Underlying vascular disorders (e.g., hereditary hemorrhagic telangiectasia, though rare).
• Age 20‑40 years (peak incidence).

Diagnosis

Because UAVM can mimic other causes of abnormal bleeding, a systematic approach is essential.

1. Clinical Evaluation

• Detailed obstetric and gynecologic history (surgeries, D&C, pregnancies).
• Physical examination focusing on genitalia, abdomen, and hemodynamic status.

2. Imaging Studies

• Transvaginal Pelvic Ultrasound (TVUS) with Doppler: First‑line tool. Shows a heterogeneous, hypoechoic uterine region with high‑velocity, low‑resistance flow (peak systolic velocity > 30 cm/s).
• Color Doppler Sonography: Highlights turbulent flow; a “color mosaic” pattern is characteristic.
• Magnetic Resonance Angiography (MRA): Provides detailed anatomic mapping, especially when planning surgery.
• CT Angiography: Useful in emergency settings to localize bleeding and assess surrounding structures.
• Conventional Pelvic Arteriography (Digital Subtraction Angiography, DSA): Gold standard; visualizes feeding arteries and nidus, guides embolization.

3. Laboratory Tests

• Complete blood count (CBC) – assess anemia.
• Pregnancy test – rule out ectopic pregnancy or miscarriage‑related bleeding.
• Coagulation profile – important before any invasive procedure.

4. Histopathology (Rare)

Only obtained if a surgical specimen is removed; confirms abnormal arteriovenous channels without intervening capillaries.

Treatment Options

Management is individualized based on severity of bleeding, desire for future fertility, and overall health.

1. Conservative Management

• Observation: Small, asymptomatic AVMs may be monitored with periodic ultrasound.
• Medical therapy: Hormonal agents (e.g., combined oral contraceptives, progestins) can reduce bleeding by stabilizing the endometrium, but they do not eliminate the vascular lesion.

2. Uterine‑Sparing Interventions

• Uterine Artery Embolization (UAE): The preferred minimally invasive option for women wishing to preserve fertility. Embolic agents (polyvinyl alcohol particles, microspheres, or coils) occlude feeding arteries. Success rates 80‑95% with rapid symptom control (Cleveland Clinic, 2022).
• Selective Transcatheter Embolization: Targets only the nidus, sparing healthy tissue.
• Hormonal Therapy Adjunct: Combined with UAE to control residual menstrual bleeding.

3. Surgical Options

• Laparoscopic or Open Excision: Direct removal of the AVM. Feasible for localized lesions.
• Hysterectomy: Definitive cure, recommended for women who have completed childbearing or when bleeding is refractory to less invasive measures.
• Uterine‑Sparing Myomectomy: Rarely performed; only when AVM coexists with fibroids.

4. Supportive Care

• Intravenous fluid resuscitation and blood transfusion for acute hemorrhage.
• Iron supplementation for chronic anemia.
• Tranexamic acid (off‑label) may be used short‑term to reduce menstrual blood loss.

5. Lifestyle Adjustments

• Avoidance of intrauterine devices (IUDs) or procedures that could traumatize the uterus until the AVM is treated.
• Maintain adequate hydration and nutrition to support vascular health.

Living with Uterine Arteriovenous Malformation

Following successful treatment, most women lead normal lives. Practical tips for day‑to‑day management include:

• Schedule regular follow‑up ultrasounds: Every 3–6 months for the first year, then annually.
• Track menstrual patterns: Keep a bleed diary; note volume, duration, and any clots.
• Manage anemia proactively: Iron‑rich diet (red meat, legumes, leafy greens) and periodic CBC checks.
• Pregnancy planning: Discuss timing with a maternal‑fetal medicine specialist. Many women conceive successfully after UAE, but close monitoring is required.
• Physical activity: Light‑to‑moderate exercise is safe; avoid high‑impact sports that may increase intra‑abdominal pressure during the acute phase.
• Emotional health: Experiencing heavy bleeding can be distressing. Seek counseling or support groups if anxiety or depression develops.

Prevention

Because many UAVMs are acquired, reducing uterine trauma lowers risk:

• Choose minimally invasive surgical techniques when possible.
• Limit unnecessary D&C procedures; consider medical management of early pregnancy loss when appropriate.
• Use skilled providers for hysteroscopic or laparoscopic surgeries.
• After any uterine intervention, schedule a follow‑up ultrasound to detect early vascular changes.
• Educate patients about early signs of abnormal bleeding so they can seek prompt evaluation.

Complications

If left untreated, UAVM can lead to serious outcomes:

• Severe hemorrhage: Can cause hypovolemic shock, requiring emergency transfusion.
• Chronic anemia: Leads to fatigue, reduced work capacity, and cardiovascular strain.
• Infertility or recurrent pregnancy loss: High‑flow lesions may compromise implantation.
• Uterine rupture (rare): Especially during labor if the AVM is large.
• Psychological impact: Ongoing bleeding may cause anxiety, depression, or sexual dysfunction.

When to Seek Emergency Care

---

References

• Mayo Clinic. “Uterine arteriovenous malformation.” 2023. www.mayoclinic.org
• Cleveland Clinic. “Uterine Arteriovenous Malformation (UAVM) – Diagnosis and Treatment.” 2022. my.clevelandclinic.org
• American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 225: Abnormal Uterine Bleeding. 2021.
• National Institutes of Health (NIH). “Uterine Arteriovenous Malformation.” 2020. NCBI Bookshelf
• World Health Organization. “Guidelines for the Management of Heavy Menstrual Bleeding.” 2021.
• J. Yang et al., “Uterine Arteriovenous Malformation: A 10‑Year Review of 45 Cases,” *Journal of Minimally Invasive Gynecology*, vol. 27, no. 4, 2020.

```